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Abstract
Background: Multiple randomized controlled trials (RCTs) have examined the cardiovascular effects of omega-3 fatty 
acids and have provided unexplained conflicting results. A meta-analysis of these RCTs to estimate efficacy and safety 
and potential sources of heterogeneity may be helpful.
Methods: The Cochrane library, MEDLINE, and EMBASE were systematically searched to identify all interventional trials 
of omega-3 fatty acids compared to placebo or usual diet in high-risk cardiovascular patients. The primary outcome 
was all-cause mortality and secondary outcomes were coronary restenosis following percutaneous coronary 
intervention and safety. Meta-analyses were carried out using Bayesian random-effects models, and heterogeneity was 
examined using meta-regression.
Results: A total of 29 RCTs (n = 35,144) met our inclusion criteria, with 25 reporting mortality and 14 reporting 
restenosis. Omega-3 fatty acids were not associated with a statistically significant decreased mortality (relative risk [RR] 
= 0.88, 95% Credible Interval [CrI] = 0.64, 1.03) or with restenosis prevention (RR = 0.89, 95% CrI = 0.72, 1.06), though the 
probability of some benefit remains high (0.93 and 0.90, respectively). However in meta-regressions, there was a >90% 
probability that larger studies and those with longer follow-up were associated with smaller benefits. No serious safety 
issues were identified.
Conclusions: Although not reaching conventional statistical significance, the evidence to date suggests that omega-3 
fatty acids may result in a modest reduction in mortality and restenosis. However, caution must be exercised in 
interpreting these benefits as results were attenuated in higher quality studies, suggesting that bias may be at least 
partially responsible. Additional high quality studies are required to clarify the role of omega-3 fatty acid 
supplementation for the secondary prevention of cardiovascular disease.
Background
Interest in the therapeutic value of fish oils began in the
1970's following the observation of a low incidence of
cardiovascular disease in Greenland Inuits [1-3]. Subse-
quently, several studies identified eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA), two major long
chain n-3 polyunsaturated fatty acids (n-3 PUFAs), as the
putative protective constituents [4-10]. The role of α-
linolenic acid (ALA), a shorter chain omega-3, is still
being debated [11]. Although the exact cardio-protective
mechanisms of omega-3 fatty acids are unknown, it has
been hypothesized that a reduction of arrhythmias, heart
rate, ischemia/reperfusion-induced injury, serum triglyc-
eride levels, inflammation, or improved endothelial func-
tion may be involved [12-17]. Multiple studies, reviews,
and meta-analyses have been conducted in order to eluci-
date the effect of omega-3 fatty acids on cardiovascular
outcomes, but controversy prevails with both positive
[18] and negative conclusions [19,20].
Omega-3 fatty acids are inexpensive compounds with
an apparent favorable risk profile including a low propen-
sity for drug interaction. Moreover, there have been sev-
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eral recent publications of randomized trials, and we
therefore decided to perform an updated systematic
review and meta-analysis of their cardiovascular efficacy.
We have, unlike previous analyses [18,19], restricted our
systematic review to high risk patients, the group most
likely to benefit from their use, and have explicitly investi-
gated potential sources of heterogeneity between these
trials.
Methods
Literature Search
We searched MEDLINE, the Cochrane Library, and
EMBASE without language restrictions for original
research articles, systematic reviews, and meta-analyses
to identify all available literature on omega-3 fatty acids
and cardiovascular disease published from January 1966
through September 2008. We combined search terms for
omega-3 fatty acids ("omega-3 fatty acids" OR "fish oil"
OR "marine oil" OR "dietary therapy") with those for mor-
tality or cardiovascular disease ("mortality" OR "cardio-
vascular disease" OR "heart disease" OR "CAD" OR "MI"
OR "UA" OR "coronary angiography" OR "coronary rest-
enosis"). References of relevant articles were hand-
searched for additional studies.
Inclusion criteria required each study to 1) be a com-
parative randomized trial involving human participants
with an active treatment arm using omega-3 fatty acids
with usual diet; 2) involve a high-risk population with
known cardiovascular disease or diabetes; and 3) report
at least 1 of the following 2 outcomes: total mortality or
coronary artery restenosis following angioplasty. We
excluded non-randomized studies, those involving chil-
dren or animals, and studies in which the omega-3/fish
supplement dosage was unspecified. We also excluded
studies in which patients were randomized to dietary
advice that included a non-quantifiable intervention of
simply increasing fish consumption [21]. The Quality of
Reporting of Meta-analyses of Randomized Controlled
Trials (QUORUM) guidelines were followed throughout
this meta-analysis [22] [See Additional file 1 - QUORUM
checklist].
Data Extraction
One author performed the literature search, and data
extraction was independently conducted by at least two
individuals. The following information was extracted:
publication details, timing of study, duration of follow-up,
randomization method, blinding (of participants, investi-
gators, and outcome assessors), omega-3 dosage, drop-
outs, mean age of participants, primary outcome (total
mortality), secondary cardiovascular outcomes (resteno-
sis, sudden death, cardiac death, non-fatal myocardial
infarction (MI), congestive heart failure (CHF), arrhyth-
mias, implantable cardioverter defibrillator (ICD) shocks,
and stroke), the proportion of patients who discontinued
treatment, side effects (gastro-intestinal (GI) side effects,
bleeding, and malignancies), and adherence. Any dis-
agreements in the collected data was resolved by consen-
sus or, when necessary, upon consultation with a third
reviewer. The authors of the original publications were
contacted to obtain missing data and resolve ambiguities
(n = 16), although we made no attempt to contact authors
of articles published before 1995.
Quality assessment of the individual trials was per-
formed using the Jadad scale [23] [See Additional file 2-
Quality assessment of included trials].
Statistical Analysis
To estimate the risk of all-cause mortality, data were ana-
lyzed according to the intention-to-treat principal; the
denominator was the number of participants randomized
to each group, and the numerator was the number of
deaths reported during the follow-up period. In our rest-
enosis analysis, the denominator was the number of par-
ticipants undergoing follow-up coronary angiography,
and the numerator was those with restenosis. In most
studies, restenosis was defined as the loss of luminal
diameter of at least 50% [24-29]. One study defined it as a
loss of 70% [30], and 2 studies defined coronary resteno-
sis as at least 50% stenosis at follow-up [31,32]. Three tri-
als used multiple definitions, including loss of luminal
diameter of at least 50% and at least 50% stenosis at fol-
low-up [33-35]. The remaining two studies used unique
restenosis definitions; one used a panel of blinded cardi-
ologists to assess changes in progression and regression
of CAD [36], and the other defined restenosis as lumens
with greater than 20% obstruction [37]. Where possible,
cardiovascular event and safety data were analyzed using
an intention-to-treat approach. However, many resteno-
sis studies presented data only for those who underwent
follow-up coronary angiography.
For each study, we estimated the risk ratio (RR) com-
paring intervention and control groups. For studies with
zero outcomes in either group, we added 0.5 to all cells of
the 2-by-2 table. For the primary outcomes of mortality
and main secondary analysis of restenosis, we fit meta-
regression models to investigate if study-level covariates
explained any of the heterogeneity in RRs across studies.
We estimated the median and corresponding 95% credi-
ble interval (CrI), the Bayesian analogue for confidence
intervals, for each coefficient in these models. In addi-
tion, we also estimated the probability that the coefficient
was greater than 0. The covariates used in the meta-
regression were median follow-up time (months), sample
size, high dosage of the intervention, high quality (on the
Jadad scale), high adherence rate, and high percentage of
previous MI. Cut-offs for defining dichotomous covari-
ates were determined by the median value across studies.Filion et al. BMC Cardiovascular Disorders 2010, 10:24
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For the all-cause mortality meta-analysis, subgroups were
defined by sample size (>322 patients), study quality (>3),
dosage of omega-3 (>3.3 g/day), adherence (>84%), and
history of previous MI (>50%). For the restenosis meta-
analysis, subgroups were defined by study quality (>3),
sample size (>233 patients), dosage of omega-3 (>5.04 g/
day), adherence (>85%), and previous MI (>48%).
W e carried out meta-analyses to pool RRs acr oss all
studies [38]. Separate models were created for each of the
primary and secondary outcomes and for safety data.
When there was greater than 90% probability that a cova-
riate was associated with the relative risk (i.e., >90% prob-
ability that the meta-regression coefficient was different
from 0), we carried out separate meta-analyses within
subgroups defined by the covariate. Funnel plots were
employed to assess publication bias.
All analyses were carried out using WinBUGS and R
software programs. Low information prior distributions
(mean 0 and a standard deviation of 100) were used for all
parameters. The between-study standard deviation in the
log (RR) was assumed to follow a uniform distribution
over the range from 0 to 5.
Results
Literature Search
Our literature search identified 9,258 titles, of which 558
articles were considered potentially relevant (Figure 1).
The full texts of these articles were retrieved, and 27 arti-
cles fulfilled our inclusion criteria [24-37,39-51]. One
trial [51] was then excluded due to concerns regarding
the authenticity of its data [52-54]. Three additional trials
were identified through our hand-search of relevant stud-
ies [55-57], resulting in a total of 29 included trials. These
trials involved a total of 35,144 patients. There were 25
articles that reported mortality [24-26,29,31,33-37,39-
50,55-57] and 14 that examined coronary restenosis [25-
37,42]. The trials reporting mortality randomized 34,501
patients (17,276 omega-3 patients and 17,190 controls),
and the restenosis trials randomized 3,553 patients to
omega-3 fatty acids (n = 1,817) or control (n = 1,736).
Study and Patient Characteristics
Although performed in a multitude of different countries,
the trials were fairly homogeneous with respect to patient
and study characteristics [See Additional file 3 - study
and patient characteristics]. All mortality trials were con-
ducted in high-risk cardiovascular patients: 4 were con-
ducted in post-MI patients [21,24,43,44], 3 involved
patients with ICDs [47-49], and 1 involved diabetic
patients [41]. The remaining 16 trials consisted of a mix-
ture of other high-risk cardiovascular patients. Most tri-
als were conducted in middle aged or older patients, and
the majority of patients were men. Trials were generally
double-blind, with either placebo or inactive oil as con-
trol, although some were open-label with control being
usual diet [28,44]. Thirteen mortality trials and 2 resteno-
sis trials had follow-up ≥ 12 months. In the mortality tri-
als, omega-3 was provided in the form of EPA, DHA,
DPA, or ALA, with dosages ranging from 0.9 g/day to 6.9
g/day. In the restenosis trials, omega-3 consisted of EPA
or DHA, with daily dosages ranging from 3 g/day to 6.9 g/
day. Follow-up varied from 1 to 55 months with a median
6 months for restenosis studies and 12 months for mor-
tality studies.
All-Cause Mortality
A total of 3,867 deaths (1,885 in omega-3 patients and
1,982 in controls) occurred in these trials. When data
were pooled across all studies, omega-3 fatty acids were
not associated with a reduction in all cause-mortality (RR
= 0.88, 95% CrI = 0.64, 1.03), though the probability of
some benefit (RR<1) remains high (0.93). The majority of
the studies were inconclusive but one individual study
with a follow-up greater than 12 months did show a sta-
tistically significant beneficial effect of omega-3 fatty
acids (Figures 2, 3).
The meta-regression models suggested with a greater
than 90% probability that larger studies and those with
longer follow-up were associated with decreasing health
benefits (Table 1). Specifically, there was a 97% probabil-
Figure 1 Flow diagram of selection process of randomized con-
trolled trials included in meta-analysis.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9,258 titles identified in literature search 
558 potentially relevant titles retrieved as 
full-texts 
8,700 titles and abstracts excluded upon 
brief inspection 
160 potentially relevant titles retrieved as 
full-texts 
398 full text articles excluded upon visual 
inspection (not relevant) 
27 articles identified in literature search 
133 full text articles excluded:
-  Patients at low or moderate 
cardiovascular risk (n=46) 
-  Cohort studies (n=31) 
-  Not randomized (n=18) 
-  Non adult, non-human (n=12) 
-  No relevant outcomes (n=9) 
-  Duplicate publications (n=8) 
-  No omega-3 arm (n=4) 
-  Omega-3 dosage unclear (n=3) 
-  Inappropriate control (n=1) 
-  Randomization to fish advice 
(n=1) 
26 articles identified in literature search 
included in meta-analysis 
1 trial with potentially fraudulent data 
excluded 
3 trials identified by hand-search of 
references 
29 articles included in meta-analysis
(15 reporting mortality, 4 reporting 
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Figure 2 Effect of omega-3 fatty acids on all-cause mortality among studies with follow-up ≤ 12 months. Arrows indicate that the lower limit 
of the credible interval for the relative risk was less than 0.2 or the upper limit exceeded 5.0.
Figure 3 Effect of omega-3 fatty acids on all-cause mortality among studies with follow-up > 12 months. Arrows indicate that the lower limit 
of the credible interval for the relative risk was less than 0.2 or the upper limit exceeded 5.0.Filion et al. BMC Cardiovascular Disorders 2010, 10:24
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ity that the effect of omega-3 fatty acids was smaller in
the 12 larger trials (RR = 0.95, 95% CrI = 0.76, 1.13) than
in the 13 trials with small sample sizes (RR = 0.47, 95%
CrI = 0.18, 0.83). Similarly, there was a 99% probability
that those with follow-up greater than 12 months (RR =
0.91, 95% CrI = 0.57, 1.12) had attenuated benefits com-
pared with those with follow-up ≤ 12 months (RR = 0.72,
95% CrI = 0.38, 1.08) (Figures 2, 3 and 4). Dosage, study
quality, adherence, and history of previous MI did not
appear to influence the results.
We also carried out a sensitivity analysis by excluding
the sole study using ALA [24], which did not change the
overall results.
Coronary Restenosis
In 14 studies that assessed omega-3 fatty acids following a
percutaneous coronary intervention (PCI), these agents
were not statistically associated with the risk of restenosis
(RR = 0.89, 95% CrI = 0.72, 1.05)(Figure 5) but again there
was a moderate probability of some benefit (probability
RR < 1 = 0.90). Subgroup analysis suggested that this
result was unaltered by dosage, follow-up, or adherence
(Table 1) but there was a 94% probability that the effect of
omega-3 fatty acids on restenosis was attenuated in larger
RCTs (RR = 0.94, 95% CrI = 0.66, 1.26) compared with
smaller ones (RR = 0.82, 95% CrI = 0.56, 1.17) and a 89%
probability that higher quality trials also exhibited attenu-
ated results.
Figure 4 Scatter plot of the change in log (risk ratio) for all-cause 
mortality with median follow-up time. Weights in the scatter plot 
are proportional to the inverse of the variance of each study's log (risk 
ratio).
Figure 5 Effect of omega-3 fatty acids on coronary restenosis. Ar-
rows indicate that the lower limit of the credible interval for the relative 
risk was less than 0.2 or the upper limit exceeded 5.0. Although 3,553 
patients were randomized to omega-3 fatty acids (n = 1,817) or control 
(n = 1,736), only 3,004 patients (1,539 and 1,465, respectively) were in-
cluded in the analyses. Patients who did not undergo follow-up angio-
gram were generally excluded from the restenosis analyses.
Table 1: Results of univariate meta-regression models relating mortality and restenosis regression coefficients to study-
level covariates*.
Mortality Restenosis
Median Regression 
Coefficient (95% CrI)
Probability that the 
Regression Co-efficient>0
Median Regression 
Coefficient (95% CrI)
Probability that the 
Regression Co-efficient>0
Follow-up time (months) 0.009 (0.003, 0.019) 0.992 0.00 (-0.03, 0.03) 0.4821
High dosage -0.48 (-1.123, 0.141) 0.059 0.05 (-0.39, 0.45) 0.6301
High quality -0.247 (-0.837, 0.39) 0.208 0.22 (-0.15, 0.65) 0.8909
High adherence rate 0.16 (-0.331, 0.529) 0.81 -0.29 (-1.16, 0.58) 0.1909
High percentage of previous MI 0.11 (-0.493, 0.434) 0.712 0.03 (-0.43, 0.54) 0.6155
Log (sample size) 0.16 (-0.005, 0.402) 0.971 0.19 (-0.07, 0.46) 0.94
Abbreviations: CrI: credible interval; MI: myocardial infarction.
*High dosage, quality, adherence, and percentage of previous MI were defined using the medians of all studies.F
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Table 2: Randomized controlled trials examining the safety of omega-3 fatty acids.
Number of Patients Discontinued Treatment GI Side Effects Bleeding Cancer
Study Fish Oil Ctrl Fish Oil Ctrl Fish Oil Ctrl Fish Oil Ctrl Fish Oil Ctrl
Borchgrevink [24] 100 100 9 9 7 7 NR NR 0†† 1††
Dehmer [31] 43 39 0 NR 7 3 3 1 NR NR
Grigg [29] 52 56 2 NR 2 1 0 0 NR NR
Milner [32] 95 99 11 0 24 NR 0 NR NR NR
Reis [30] * 124* 51* NR NR 59 11 4 0 NR NR
Nye [39] 36 37 NR NR NR NR NR NR NR NR
Bairati [33] 59 60 NR NR NR NR 0 0 NR NR
Bellamy [28]† 60 60† 30 ‡ 5 0 NR NR NR NR
Kaul [27] 58 49 NR NR 2 0 0 0 NR NR
Franzen [34]§ 103§ 101§ 6 7 14 10 0 0 NR NR
Leaf [25] 226 221 2 7 16 18 7 7 NR NR
Sacks [37]¶ 41¶ 39¶ 6 1 NR NR 0 0 NR NR
Cairns [26] 325 328 NR NR 122 101 17 38 NR NR
Eritsland [40] 317 293 41 25 40 30 5 4 NR NR
Rossing [41] 18 18 4 3 3 1 0 0 1 1
Johansen [42]|| 196|| 192|| NR NR 3 2 NR NR NR NR
von Schacky [36] 111 112 14 15 4 3 0 0 0 0
Nilsen [43] 150 150 NR NR NR NR NR NR 2** 0**
Durrington [56] 30 29 1 1 1 1 0 0 0 0
Marchioli [44] 5666 5658 1616 687‡ 2 7 8N RN RN R 1 4 2 1 3 4
Maresta [35]†† 146†† 141†† N R N R 2263 N R N R
Burr [45] 1571 1543 NR NR NR NR NR NR 51** 47**
Calò [46] 79 81 NR NR NR NR 1 1 NR NR
Leaf [47] 200 202 73 69 NR NR NR NR NR NR
Raitt [48] 100 100 17 26 11 12 NR NR 3 4
Brouwer [49] 273 273 23 18 17 12 NR NR 4 4F
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Yokoyama [50]‡‡ 9326 9319 1087 673 352 155 105 60 242 218
GISSI-HF[55] 3494 3481 102 104 96 92 NR NR NR NR
OMEGA-Trial [57] 1919 1885 NR NR NR NR 35 34 NR NR
Relative Risk (95% CrI) 1.23 (0.87, 1.68) 1.29 (1.02, 1.61) 0.85 (0.52, 1.27) 1.02 (0.73, 1.25)
Abbreviations: Ctrl = control; GI = gastrointestinal; NR = not reported.
* Reis et al. [30] randomized 222 patients, 204 of which underwent angioplasty. Of these patients, 14 patients had unsuccessful angioplasties and 4 other patients underwent bypass surgery 
following their angioplasty. These 18 patients were excluded from further study. The remaining 186 patients were included in the study, including 124 patients in the fish oil group (60 randomized 
to ethyl ester fish oil, 64 randomized to triglyceride fish oil) and 62 randomized to placebo. Clinical event data were available for all patients however 11 patients in the placebo group did not provide 
side effect data. Thus, side effect analyses are based on 124 fish oil patients and 51 placebo patients.
† The control group involved a total of 60 patients, 53 of which underwent follow-up angiography and 7 of which who did not. Consequently, the sample size of the control group is 53 patients for 
baseline and restenosis data but 60 patients for all other analyses.
‡The study by Bellamy et al. [28] did not involve the use of placebo and thus, treatment discontinuation data were not presented for the control group. The study by Marchioli et al. [44] was a factorial 
design in which the control group was comprised of 2,830 patients randomized to vitamin E and 2,828 patients randomized to control. Discontinuation data were not available for those randomized 
to control.
§In the study by Franzen and colleagues [34], 204 patients were randomized to fish oil (n = 103) or placebo (n = 101). However, only 175 patients underwent angiographic follow-up (92 fish oil and 
83 placebo). Consequently, the sample size for restenosis should be a total of 175 patients whereas the sample size for all other analyses should be 204.
¶Sacks and colleagues [37] randomized 80 patients to fish oil (n = 41) or control (n = 39). A total of 21 patients were excluded from the study prior to undergoing their follow-up angiogram. Although 
clinical events were assessed in all 80 randomized patients, restenosis was only assessed in 59 patients (31 fish oil, 28 controls).
||Johansen and colleagues [42] randomized a total of 500 patients to omega-3 fatty acid (n = 250) or placebo (n = 250). Of these patients, 5 were disqualified before their angioplasty (4 omega-3 
patients and 1 placebo patient), 103 were disqualified during their angioplasty (n = 49 and 54, respectively), and 4 patients were excluded because they died prior to their follow-up angiogram (1 
omega-3 patient and 3 patients randomized to placebo). There were therefore 196 patients randomized to omega-3 fatty acids and 192 patients randomized to placebo who were ultimately 
included in the study. The cardiac death analyses are based on 197 patients randomized to omega-3 fatty acids and 195 patients randomized to placebo whereas all other analyses are based on 
196 and 192 patients, respectively.
**Data obtained from previous Cochrane review [19].
†† Maresta et al. [35] randomized 339 patients (169 to fish oil, 170 to placebo). Of these patients, 52 were disqualified before or at their angioplasty, leaving 287 patients (146 fish oil, 141 placebo). 
Side effect and clinical event data are based on these patients. An additional 23 patients were unevaluable drop-outs, leaving 264 patients (129 fish oil, 135 placebo) with 6-month angiograms 
available, and 7 additional patients were excluded because quantitative coronary angiography was not possible, resulting in a total of 257 patients (125 fish oil, 132 placebo) being included in the 
restenosis analyses.
‡‡The JELIS Trial [50] (conducted by Yokoyama) was performed on a population with low, moderate and high risk cardiovascular patients. Due to the lack of data, cardiovascular instead of all-cause 
mortality was used for the secondary prevention group. Demographic and cardiovascular outcome data are presented for the high-risk group (n = 3,664) whereas safety data are presented for the 
entire study population (n = 18,645). The JELIS cardiovascular data were included as part of our pooled analysis. However, due to the heterogeneity of the entire study population, data from the 
JELIS trial were not included in our pooled analysis of safety data.
Table 2: Randomized controlled trials examining the safety of omega-3 fatty acids. (Continued)Filion et al. BMC Cardiovascular Disorders 2010, 10:24
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Other Cardiovascular Events
Although the point estimates suggest that omega-3 fatty
acids may reduce other cardiovascular events, including
cardiac death, sudden death, non-fatal MI, CHF, arrhyth-
mias, and ICD shocks, the wide CrIs prevent definitive
conclusions from being drawn [See Additional file 4 - sec-
ondary cardiovascular outcomes].
Safety
Few studies reported side effect and safety data (Table 2).
Patients randomized to omega-3 fatty acids did have an
increased risk of GI side-effects (RR = 1.29, 95% CrI =
1.02, 1.61). However, the risk of treatment discontinua-
tion was similar between groups (RR = 1.23, 95% CrI =
0.87, 1.68), suggesting that these side-effects were rela-
tively minor. There was no increased risk of malignancies
(RR = 1.02, 95% CrI = 0.73, 1.25) or bleeding (RR = 0.85,
95% CrI = 0.52, 1.27), but wide 95% CrI again prevent
definitive conclusions from being drawn regarding these
outcomes.
Funnel plots did not provide any clear indication of
publication bias (data not shown).
Discussion
Our systematic review and meta-analysis assessed the
effect of omega-3 fatty acids on all-cause mortality and
coronary artery restenosis following PCI among high-risk
cardiovascular patients. Omega-3 fatty acids were not
associated with a statistically significant reduction in all-
cause mortality or restenosis but the probability of a
modest benefit remains considerable. Omega-3 fatty
acids also had generally favorable effects on other cardio-
vascular outcomes, but definitive conclusions are not
forthcoming due to the small number of studies that
reported these outcomes. Unfortunately, the majority of
trials did not systematically record adherence and side
effects. Nevertheless, the available data suggest a favor-
able side-effect profile.
Our meta-regression identified some important
sources of heterogeneity among mortality trials, includ-
ing trial size and follow-up time. Specifically, larger and
longer trials had smaller mortality benefits, suggesting
that the overall observed benefit may be at least partially
inflated due to bias. Similarly, restenosis benefits were
smaller in larger, better quality trials. These findings tem-
per our enthusiasm for this intervention despite a rela-
tively favorable risk profile. Definitive results about the
efficacy and safety of omega-3 fatty acid supplementation
will benefit from the results of currently ongoing clinical
trials, including ORIGIN [58] and ASCEND [59].
The effect of omega-3 fatty acids has been examined in
previous systematic reviews and meta-analyses. However,
these earlier meta-analyses [19,60,61] were not limited to
high-risk cardiovascular patients, included a scientifically
questionable study [51], did not have access to the most
recently published large studies of 15,000 high-risk car-
diovascular patients [47-50,55,57], and importantly, did
not explicitly investigate potential sources of heterogene-
ity which permits a more nuanced interpretation of the
totality of evidence. Our results are similar to previous
focused meta-analysis examining restenosis [62] and ICD
shocks [61,63]. However, our credible intervals are
slightly wider as our Bayesian methods account for
uncertainty in the between-study variability.
Strengths and Limitations
Our systematic review and meta-analysis has a number of
strengths. First, it provides a complete and comprehen-
sive review of the current state of the omega-3 fatty acid
literature. In several cases, the published data of this sys-
t e m a t i c  r e v i e w  h a v e  b e e n  c o m p l i m e n t e d  b y  a d d i t i o n a l
data furnished by the principal investigators of the origi-
nal studies. Second, our Bayesian models, unlike their fre-
quentist counterparts, allow for the calculation of
probabilities and therefore have a more intuitive and
informative interpretation. Third, our systematic review
and meta-analysis was conducted according to a pre-
specified protocol, including pre-specified subgroup
analyses, and without language restrictions. Fourth, we
have addressed not only the efficacy but also the safety of
omega-3 fatty acids. Finally, although previous reports
have discussed the role of heterogeneity in the literature
[64], we examined the sources of heterogeneity analyti-
cally. Consequently, we have provided a thorough and
methodologically rigorous synthesis of the available evi-
dence thereby facilitating informed decision making.
Nevertheless, our systematic review and meta-analysis
does have potential limitations. First, as is true with all
systematic review and meta-analyses, our study may be
affected by publication bias, although we did not find evi-
dence of its occurrence. Second, there was some hetero-
geneity in study design, including in dosage of omega-3
fatty acid used and patient populations. In particular,
there is much uncertainty regarding the potency and
purity of over-the-counter formulations while the propri-
etary formulation is both expensive and has been infre-
quently used in the clinical trials. Moreover, the control
groups were exposed to varying amounts of fish oils
according to national dietary habits, and we could not
account for this variability. Our random-effects models
attempt to account for between-study variability, and the
effects of this heterogeneity were examined in our meta-
regression models. Third, safety data were not reported
in all studies. Fourth, due to the fish odor of omega-3
fatty acid supplements, complete blinding of fish oil stud-
ies may not be feasible. This imperfect blinding was not
considered in our quality assessment. Fifth, most resteno-
sis studies only presented data among those who com-Filion et al. BMC Cardiovascular Disorders 2010, 10:24
http://www.biomedcentral.com/1471-2261/10/24
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pleted their follow-up angiogram. Consequently,
restenosis data were generally analyzed using a modified
intention-to-treat, which may result in biased results.
Finally, due to the lack of individual-level data, we were
not able to estimate the change in risk of mortality or car-
diovascular outcomes over time. We therefore assumed
that the risk of the outcome remained the same across the
duration of each study and that any censoring was ran-
dom. Availability of individual-level data would also have
allowed us to estimate the effect of patient-level covari-
ates and to examine which subgroups may derive the
greatest benefit from the use of these agents.
Conclusions
This meta-analysis demonstrates that omega-3 fatty acid
supplementation may modestly reduce all-cause mortal-
ity and restenosis when used as secondary prevention.
However, the mortality benefit was attenuated in larger
RCTs and those with longer follow-up, and the restenosis
benefits were similarly reduced in larger RCTs. These
results suggest that bias may at least partially explain the
observed benefit. Also, many studies had incomplete
information on other cardiac endpoints and adverse
events. Further ongoing studies with sufficient sample
size, standardized dosing, and adequate follow-up dura-
tion are required to clarify the role of omega-3 fatty acid
supplementation for the secondary prevention of cardio-
vascular disease.
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